Chinese pathogenic microorganisms and immunologists
Academician of the Chinese Academy of Sciences
Foreign Academician of the National Academy of Sciences of the United States
Foreign Academician of the Royal Society of the United Kingdom
Academician of the German National Academy of Sciences
Foreign Academician of the Russian Academy of Sciences
Director of the Academic Committee of the Institute of Microbiology of the Chinese Academy of Sciences
Director of the Key Laboratory of Pathogenic Microorganisms and Immunology of the Chinese Academy of Sciences
Chairman of the Chinese Bioengineering Society
Vice President of the Chinese Medical Association

A recognised expert in cancer immunotherapy, has been recognised as a Highly Cited Researcher by Clarivate for seven consecutive years since 2018 and received the Biology and Biochemistry Leader Award (Research.com) in both 2022 and 2023. He is considered among the world’s most influential scientists in the fields of biology and biochemistry.

The founder and director of the Immunology Department at Ramon Yacar Hospital;
As one of the co-authors, he worked with Nobel laureate J. Dizet to formulate the current Spanish organ transplantation law. This achievement was recognized by the Senate in 2016;
Approved by the International Review Committee, he was appointed as a professor at the Spanish University, responsible for pioneering the field of immunology at the Spanish University. This appointment was made together with Professor Ortiz de Landa Zuri and Professor Sanchez Madrid;
The founder, as the first professor of the Immunology Department at the University of Complutense Madrid (now promoted to full professor);
The founder of the European Immunogenetics Foundation;
Elected president of the Spanish Immunology Society.

Member of the Bacteria and Archaea Division of the International Committee on Taxonomy of Viruses
Member of the Microbiology and Immunology Professional Committee of the Chinese Medical Association
Standing Committee Member of the Medical Microbiology and Immunology Professional Committee of the Chinese Society for Microbiology (Head of the Bacteriophage Group)
Member of the Bioinformatics and Computational Biology Professional Committee of the Chinese Biotechnology Society

A translational cancer biologist with more than 40 publications in high-tier journals. The work mainly focuses on mitigating prostate, breast and lung cancers by rewiring the tumor suppressor RB via small molecular inhibitors and ionizing radiation.

Researcher in Lille University Hospital, France (CNRS-UMR 8576, Inserm U1285). He was a research fellow in Cleveland Clinic (Cleveland, OH), before returning to Lille University Hospital in 2012. He received my Ph.D. in immunology-microbiology in 2006 from Lille University. He Is interested in how the human pathogenic yeast Candida albicans may manipulate host innate immune pathways during the intestinal inflammation to cause disease.

Assistant Researcher of the Biotechnology Center at Minho University

His research aims to completely understand the various steps of the virus cycle, including the entry, replication and assembly using a combination of structural analysis, cellular assays, virological, reverse genetics and animal studies. The study of virus cycle facilitates the design of better antiviral compounds and vaccines, which is in agreement with our commitment to translate our research findings into health benefits.

Dr. Yang has published over 70 papers across prestigious international journals including Cell Research, European Urology, Cancer Research, Clinical Cancer Research, Molecular Cancer, Journal of Experimental Medicine, Chemical Engineering Journal, EBioMedicine, and Critical Reviews in Food Science, with over 1000 citations. Additionally, he has published 8 professional books. He has led or participated in 14 projects funded by the Ministry of Science and Technology, the National Natural Science Foundation of China, and other national and local government agencies. Furthermore, he has applied for 23 Chinese invention patents with 12 granted. He has obtained the Shenzhen Science and Technology Progress Award (First Prize) in 2020 and the Outstanding Paper Award of Journal of Bioengineering in 2021.

Highly cited scientist, Clarivate Analytics
National Outstanding Young Scientist Award recipient
Changjiang Scholar Professor

2015 Croucher Senior Medical Research Fellowship
The Croucher Foundation Hong Kong
2013 Director
Research Centre of Infection and Immunology
Li Ka Shing Faculty of Medicine, The University of Hong Kong
2013 Convener
Strategic Research Theme of Infection and Immunology
The University of Hong Kong.
2008 Member
Coronavirus Study Group
International Committee for Taxonomy of Viruses
2006 Outstanding Young Researcher Award
The University of Hong Kong
1990 Ho Kam Tong Prize in Community Medicine
Faculty of Medicine, The University of Hong Kong

Associate Professor at Department of Pharmacy, University "G. d'Annunzio" of Chieti - Pescara
1999 – 2004, M.Sc. in Pharmacy, University of Catanzaro “Magna Græcia”
2008 – 2012, Ph.D. in Pharmaceutical Science, University of Catanzaro “Magna Graecia”:
“Supramolecular vescicular aggregates: innovative drug delivery systems for anticancer therapy”,
mentor: Prof. Donatella Paolino (S.S.D. CHIM/09 – Applied Pharmaceutical Technology).
Main research fields: design, preparation, physicochemical characterization and in vitro and in
vivo evaluation of Supramolecular Nanotherapeutics for local and systemic delivery of bioactive
compounds.

He is an internationally recognized expert in virology and immunology, with outstanding contributions to microbiology, infectious disease control, and emerging pathogen research.

He has been named a Highly Cited Researcher by Clarivate in both Microbiology and Immunology from 2021 to 2024 and has been ranked among the top 1% of global scientists since 2015. He is also listed among the top 2% most-cited scientists globally by Stanford University since 2019. In 2024, he was elected as a Member of the Hong Kong Young Academy of Sciences and received the prestigious RGC Research Fellow Award from the Research Grants Council of Hong Kong.

One of his first-author publications, published in The Lancet, was selected in 2023 as one of the 34 landmark papers in the journal’s “200 Years of The Lancet” timeline. His scientific contributions have earned numerous international accolades, including the 2023 Dalton Horizon Prize from the Royal Society of Chemistry, a Gold Medal at the 48th Geneva International Exhibition of Inventions, and the 8th VCANBIO Innovation Breakthrough Award in Biomedical Sciences.

He has also received multiple early-career honors, such as the Biomedicines and Pathogens Young Investigator Awards (2021), the Gold Medal for Best Original Research by Young Fellows from the Hong Kong Academy of Medicine (2021), and the State Scientific and Technological Progress Award (2nd Class) from the Chinese Government (2019). He is a Fellow of the Infectious Diseases Society of America (FIDSA), the Royal Society of Biology (FRSB), and the Institute of Biomedical Science (FIBMS). Since 2017, he has served as the American Society for Microbiology (ASM) Young Ambassador to Hong Kong.

His research has significantly advanced our understanding of virus transmission dynamics and therapeutic development, especially during the COVID-19 pandemic, where his team’s discoveries played a key role in early identification and response strategies.

Professor of Physics, The University of Texas at Arlington.

Education:

Ph. D. in Chemistry, 1992, Peking University, Beijing, China

MS in Crystallography, 1988, Central South University, Changsha, China

BS in Mineral Chemistry, 1985, College of Earth Science, Jilin University, Changchun, China

Awards:

Distinguished young scientist award by the Chinese Academy of Sciences, 1997

Honor award for the distinguished achievement in Science & Technology by State Education Commission of China, 1995

Honor award for the achievement in Science & Technology by Peking University,1994

Research Excellent Award, University of Texas at Arlington, 2008, 2009, 2010

Dr. William Cho is a biomedical scientist at the Department of Clinical Oncology, Queen Elizabeth Hospital in Hong Kong. With a strong background in cancer biomarker discovery and translational research, Dr. Cho has published extensively in peer-reviewed journals. His research interests include genomics, proteomics, and liquid biopsy in oncology. He actively serves on editorial boards and is a frequent reviewer for international scientific journals.

He is currently mainly engaged in clinical work at the University of California, Los Angeles.
He works at Romatol Vitorgia General Hospital, where he is a doctor.
He is competent and authorized.
He is also a qualified doctor for research institutions and public institutions.
Private.
In 2021, he was certified by the National Science as eligible to become a teacher
(SC 06/M2).
In January 2022, he won through the RtdB benchmark procedure.
He is an expert in the field of professional medicine, engaged in teaching and research
at the medical school and the professional medical school. It's done.
Furthermore, there are many teaching tasks in the professional degree courses,
including a master's degree in health and university.
He is an executive member of the regional branch of the Italian Professional Medical Association.

Dr. Sharon Shui Yee Leung received her B. Eng. (Chemical Engineering) in 2007 from the Hong Kong University of Science and Technology and completed her PhD (Chemical Engineering) in the University of Sydney in 2012. After her PhD, she joined the Faculty of Pharmacy in the University of Sydney with interest in developing technology platforms for the production of engineering particles for respiratory delivery. In 2014, she was awarded a Postdoctoral Fellowship from the Faculty of Pharmacy to develop technologies for aerosol delivery of bacteriophages to combat multidrug-resistant (MDR) bacteria. Sharon joined the School of Pharmacy at the Chinese University of Hong Kong in April 2018. Her research focuses on incorporating engineering approach with formulation designs to advance the science and potential application of phage and phage-encoded proteins as novel antibacterial agents to address the threats associated with MDR bacteria.

Our research is aimed at understanding virus-host interactions that regulate pathogenesis and outcome of RNA virus infections. Currently, work in the Li laboratory is centered on two main themes. The first one is to dissect host responses to infections by positive-strand RNA viruses including hepatitis C virus and related flaviviruses and human coronaviruses. We are particularly interested in how these viruses interact with the innate immune signaling pathways via the Toll-like receptors and RIG-I-like receptors to modulate antiviral and inflammatory responses. We are also interested in host factors that govern coronavirus replication fitness and disease severity. The second focus area is to investigate how TRIM56, a tripartite motif protein, contributes to innate antiviral immunity. Studies are ongoing to delineate the molecular determinants by which TRIM56 restricts RNA virus infections and by which it promotes innate immune signaling. To study these themes, we employ a combination of biochemical, cell biological and molecular approaches. We leverage viral infection models in cell culture and laboratory mice to identify molecular targets for investigation in vitro and in vivo.

Broadly, our focus is on developing novel nanomedicine approaches to meet unmet needs in treating, diagnosing or preventing disease. We strive to use good engineering principles to iteratively design, synthesize, characterize, test and validate next generation nanoparticles and biosensors with the ultimate goal of making a translational impact on improving human health. Developing safer, organic nanoparticles that will allow superior treatment options for cancer therapy is a major research thrust.

Dr. Martinez-Sobrido is continuing his work with the New York Influenza Center of Excellence, which is part of the National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance (CEIRS) program through the National Institutes of Health. In addition to characterizing the influenza virus, as part of this project, he is working with collaborators to develop a universal flu vaccine with the use of broadly neutralizing antibodies (bNAbs) or blood proteins that can recognize key pieces of the virus to help a person’s immune system clear infected cells from the system. Studies are underway to test these bNAbs in small animal models and suitable candidates will move into nonhuman primate models.

He teach Parasitology and Parasite-Host interactions for graduate and undergraduate students at UNICAMP (State University of Campinas, Campinas - Sao Paulo, Brazil). His main interest in basic science is focused on understanding the mechanisms that allow Leishmania to survive in the intracellular environment. In his Lab, we also study the efficacy of several compounds aiming at the discovery of novel/repurposed drugs for  leishmaniasis treatment.

Dr. Justyna Mozejko-Ciesielska currently works in the Department of Microbiology and Mycology at the University of Warmia and Mazury in Olsztyn, Poland. Her research interests are focused on the microbial synthesis of polymers. She puts a great effort into the high-throughput screening of potentially new bacteria that are able to produce polyhydroxyalkanoates. She pursues to optimize novel bioprocesses utilizing waste feedstocks in the fermentation processes. Besides, she attempts to understand the genetic and metabolic regulation that drives PHAs synthesis and accumulation.

Giuseppe Murdaca has received his PhD in Science and Space Engineering at the University of Genova (Italy) during the period of 2000-2003. Currently, he is working as Assistant professor in Internal Medicine University of Genova (Italy).

His research has included Immunodeficiency Autoimmunity Neuro-endocrino-immunology Pharmacogenomics.

Based on this research and fellowship training he has received several awards and honors, such as:
Prize for young researchers of the study, assigned by the GILS, with the following motivation: "Standardization of a method to assess impairment by skinfold thickness skin", delivered on the occasion of the "Day VII Italian to fight Scleroderma" (Milan, 17/3 / 2001).

Award for one of the three best oral presentations at the Ninth Congress of the Inter-SIMI Piemonte and Valle D'Aosta, Liguria (Genoa, 06.17.2004): Murdaca G., Fenoglio D., M. Setti, Brenci S., Villa R., Pontali E., A. Kunkl, Indiveri F., Puppo F. "Generation of CD4 + lines specific for Pneumocystis carinii and Candida albicans obtained from HIV + patients. Meaning of the coexpression of IFN-? and IL-4 ".

Dr. Valentyn Oksenych is currently a Norwegian researcher at the University of Bergen, Bergen, Norway. He graduated from the University of Strasbourg's Institute of Genetics and Molecular and Cellular Biology (IGBMC) in 2009. He was a postdoctoral fellow at Harvard University from 2010 to 2014 and at the University of Copenhagen from 2014 to 2015. In 2017, he was awarded a research grant by the Norwegian Cancer Society for his studies in cell responses to DNA damage and the significance this has for cancer and developmental disorders in the nervous system. Overall, he has obtained a dozen grants in Norway, Denmark, Sweden, and France to support his externally-funded research group in Triondheim (2016-2022). He came to NTNU as a participant in the Star Program 2017–2021 in connection with the Research Council of Norway Young Talent Grant. Furthermore, since 2020, he has been employed as a researcher at the Universities of Oslo and Bergen, as well as an invited lecturer at Stavanger. His research topics mainly include DNA repair in cells, B cell development, and DNA damage response.

• Italian Society of Microbiology, SIM
• Italian Association of Clinical Microbiology, AMCLI
• European Society of Clinical Microbiology and Infectious Disease, ESCMID 

He conducted postdoctoral research at the University of Milano, using proteomics and mass spectrometry to improve animal welfare and combat antibiotics. He also did a two-year postdoctoral research at the University of Reading in the UK, using large-scale mass spectrometry to diagnose bovine mastitis and study the spectrum of antibiotics. 
Since July 2020, he has been a researcher at the University of Magna Graecia in Catanzaro, and is also the coordinator of the project "Development and Sustainability of Typical Animal Production: Traceable and Improved Slaughtering Methods for Calabrian Dairy Products". The research activities aim to study animal welfare by applying veterinary pharmacology and toxicology sciences under the umbrella of public and global health (a single health approach).

Dr. Md. Tanvir Rahman is a Professor in the Department of Microbiology and Hygiene, Faculty of Veterinary Science at Bangladesh Agricultural University and former Director of International Desk, and Director of Prof. Mohammad Hossain Central Lab of Bangladesh Agricultural University.

He is also a Fellow of the Bangladesh Academy of Science (BAS). He is an Adjunct Visiting Professor of Xinxiang University, Henan, China. Dr. Rahman completed DVM from Bangladesh Agricultural University (BAU) in 1993. Later he completed MSc and PhD from University of Guelph, Canada and University of Warwick, UK respectively and Postdoc from the Max-Planck-Institute for Terrestrial Microbiology, Marburg, Germany.

He is an internationally recognized chemist and nanoscientist, known for his pioneering work in chemical biology and nanotechnology. He has been named a Highly Cited Researcher by Clarivate/Web of Science multiple times, and is a Fellow of both the American Association for the Advancement of Science and the Royal Society of Chemistry (UK). His accolades include prestigious lectureships such as the Langmuir Lecturer (ACS, 2010), Bioorganic Lectureship (Royal Society of Chemistry, 2016), and Cedric Hassell Lecturer (2014). He has received several major awards recognizing research and teaching excellence, including the NSF CAREER Award, Sloan Fellowship, Dreyfus Teacher-Scholar, Cottrell Scholar, and the Research Corporation’s Transformational Research and Education Award. He has held visiting and guest professorships at leading institutions including the Chinese Academy of Sciences and Ecole Normale Supérieure de Cachan. His contributions span decades of impactful research, innovation, and mentorship in the field.

Biologist with high degree in immunology with experience in immunopharmacology and PhD in immunology, studying the aspects of chronic pulmonary inflammation and tissue repair, pharmacological mechanisms and regulation. Expertise in animal models of pulmonary diseases such as pulmonary fibrosis, asthma, Influenza H1N1 infection, Aspergillosis, Acute Lung Injury, silicosis, lung metastasis of mammary tumors, and pleurisy. Background in GPCR and chemokine system biology related to immunology, inflammation, angiogenesis and fibrogenesis, with a multidisciplinary knowledge on the fields of Pharmacology, Biochemistry, Lung Pathology, Infection Diseases and Cancer. Experience drug administration and pharmacological screening in mice.

Currently he is working as a post-doctoral researcher at the Italian Institute of Technology. Here, he focus more on neuroimmunology and gene imprinting architecture in glial cells.

Dr. Saturnino Carmela is a distinguished academic and researcher in the field of pharmaceutical sciences. She earned both her undergraduate degree in Pharmacy and her postgraduate degree in Pharmaceutical Chemistry from the University of Naples, where she later completed her Ph.D. in Pharmaceutical Sciences. Throughout her academic journey, Dr. Carmela was the recipient of numerous scholarships in recognition of her outstanding research contributions.

Currently, she serves as a Professor in the Department of Sciences and Medicinal Chemistry at the University of Basilicata. Her research interests lie in pharmaceutical chemistry and drug development, and she has published extensively in several high-impact, peer-reviewed journals.

Dr. Carmela is an active member of various international scientific societies and regularly participates in global conferences, contributing her insights and staying abreast of the latest developments in her field. Her dedication to advancing pharmaceutical research and education has made her a respected figure among her peers and a mentor to aspiring scientists.

As a Scientific Advisor to the Surgeon General and the Director of Molecular Diagnostics for the USAF-EOS program, He has project management experience, dealing with research groups at the USAF Surgeon General’s Office, AFIP, NHRC, NRL and LAFB (see below for an acronym key), as well as arranging, directing and managing contract work with Commonwealth Biotechnologies, Inc. and Virapur, Inc.  His lab’s current focus is in software tools development for whole genome data mining and analyses, and in the genomic and bioinformatics analysis of adenovirus genomes, with emphasis on the evolution and natural variation of these genomes.

After postdoctoral training in molecular immunology from Weill Medical College of Cornell University, Dr. Shen spent seven years at MIT Center for Cancer Research and Department of Biology as a research scientist for high throughput technology and computational method development. Prior to joining IHI at UMN, Dr. Shen worked at Boston University Medical School as an assistant professor for two years and NYU Langone Medical Center as an associate professor for six years for teaching and research at the area of genomics and bioinformatics. From 2007 to 2008, Dr. Shen also spent two years at Helicos Bioscience for the next generation sequencing technology development. Dr. Shen completed undergraduate and graduate education from Nantong Medical College and Suzhou Medical College, respectively in China.

A member of numerous professional organizations that include the American Association of Immunology and American Society for Microbiology (ASM). I have served on numerous NIH and other grant review panels, member of Editorial Board of the ASM journal, Infection and Immunity, Chair of the Association of Medical School Microbiology and Immunology Chairs committee on Education. He was the Division Chair for Division G (mycoplasmology) for the ASM. He has received several awards from our institution, including Academic Commendation of Excellence, Benjamin L. Cohen, Award for Outstanding Research Achievement, and President’s Award for Research Excellence.

An Assistant Professor at the Faculty of Dentistry, National University of Singapore (NUS), Singapore, with affiliate positions in the Department of Biomedical Engineering and the NUS Centre for Additive Manufacturing. Trained as a dentist and bioengineer, research focuses on the application of cutting-edge technologies like 3D bioprinting and microfluidic organ-on-chip to develop novel approaches for understanding and treating periodontal disease. Further, by combining 3D bioprinting with artificial intelligence, his team develops novel strategies for fabricating personalized grafts for periodontal tissue regeneration.

Dr. Srivastava has served as a professor and eminent scientist in major US Universities. He has been proclaimed as an eminent scholar by the Kansas Bioscience Authority, and endowed professor at KUMED. The list of accolades and awards conferred on him is huge and rightly deserved too as he has been a pioneer in some trailblazing subjects when it comes to research. He has received national merit awards and scholarships during his graduate and postgraduate studies. He was awarded fellowships at the National Institutes of Health, and the National Academy of Sciences, USA, and a Career Development Award from the US Army. Furthermore, he has been rightly touted as a Scholar by Louisiana Cancer Research Consortium.

Dr. Sun (http://www.sunlab-usf.com/) is a tenured Professor with early promotion in the Department of Molecular Medicine, Morsani College of Medicine at the University of South Florida (USF). He holds affiliation appointments in the Department of Internal Medicine, Department of Molecular Bioscience, Department of Chemistry at USF, and USF Genomics. He obtained his Ph.D. in Natural Sciences (magna cum laude) from the University of Kiel, Germany, followed by postdoctoral training in Molecular Microbiology and Biochemistry at Brown University, USA. Dr. Sun's research focuses on microbial pathogenesis and host-pathogen interactions, with a particular emphasis on Clostridioides difficile (C. difficile) pathogenesis and the development of novel therapeutics, including vaccines, to prevent and treat C. difficile infection (CDI). He is nationally and internationally recognized for his contributions to vaccine / therapeutic development against CDI as well as the understanding of C. difficile pathogenesis. His work has been continuously funded by the NIH since 2012. He has actively served NIH study section panels, including as chair. Additionally, he is an Associate Editor for Microbiological Research, Molecular Medicine, and Frontiers in Immunology, and serves on the editorial boards of Infection and Immunity and Applied and Environmental Microbiology. He received the “Tufts Institute for Innovation Inaugural Award” in 2014, the “Faculty Outstanding Research Achievement Award” in 2018, and the “Excellence in Innovation Award” in 2020 at USF. He also chaired the Research Committee at the USF College of Medicine from 2019 to 2020. Since 2021, he has served as President, Vice President, Secretary, and Executive Committee member of the USF Chapter of the National Academy of Inventors (NAI), USA. In 2025, he was elected to be the “Senior Member” of NAI. He enjoys music, workout, and cuisines from different cultures during spare time.

1. Accomplished medical bacteriologist, biomedical scientist, and molecular biologist with six years of post-doc
experience with animal infection model expertise. An individual with proven I.R.B., IACUC protocol handlings, ten
years of experience as a basic science researcher, and seventeen years of hands-on experience as a bacteriologist.
2. Results-driven team player, with practical knowledge and experience in analytics (descriptive, inferential, and
predictive) and along with nine years of international experience (India, South Korea, and the USA).
3. Active communicator, an excellent scientific writer with a published cumulative impact factor of 110, and problem
solver with project management experience ranging from short-term to full-scale self-funded and other working
projects. 

Giovanni Vozzi is Full Professor in Bioengineering. He is lecturer of Laboratory of Bioengineering and Chemical Bioengineering at I level of Biomedical Engineering, and of Micro and nano systems at II level of Biomedical Engineering. He acts as supervisors of PhD students in Materials Engineering and Biomedical Engineering and coordinates the work of several undergraduate students and graduate fellows. He was supervisor of 80 Master Degree thesis in Biomedical Engineering. He acts as reviewers for the most important journal in his field.He is member of Directors board of International Society for Biofabrication, of the Technical Committee on Biomanufacturing of American Society of Mechanical Engineering, of IEEE and Of National Group of Bioengineering.

Dr. Yuntao Wu is a professor at NCBID, George Mason University, Manassas, Virginia, USA. He has been studying viruses for over 30 years, and for the past 20 years, he has been primarily focused on studying HIV infection of blood CD4 T cells and macrophages. Dr. Wu received his Ph.D. in Molecular Virology from Queen’s University, Kingston, Ontario, Canada. He received his postdoctoral training at NIH, studying HIV-1 pre-integration transcription in blood resting CD4 T cells (Science, 2001, 293:1503). Currently, his lab studies chemokine co-receptor signaling and role of cofilin in HIV infection and pathogenesis (Cell, 2008, 134:782; Science Advances, 2019, 5:eaat7911). Recently, his lab also studies the mechanisms of PSGL-1 restriction of HIV infectivity (Nature Microbiology, 2019, 4:8132)

Chief physician and docent, currently works at the Occupational and Environmental Medicine, Clinical Medicine Unit, Department of Health, Medicine and Caring Sciences, Linkoping university , Sweden, with clinical occupational medicin, medical education and biomedical research on i) gender/sex differences in atherosclerotic vascular diseases and related sickness absence; ii) mapping of exposures and lung function in real time in patients with work-related asthma.

Dr. Koichi Yuki obtained his M.D. from the University of Tokyo, Japan. After his initial medical training in Japan, he came to US and completed his surgical internship in the University of Hawaii, anesthesia residency in Massachusetts General Hospital, followed by pediatric anesthesia fellowship and pediatric cardiac anesthesia fellowship in Boston Children’s Hospital. He is currently an Associate Professor of Anaesthesia at Harvard Medical School and an Associate in Cardiac Anesthesia at Boston Children’s Hospital. He did postdoctoral research fellowship under Drs. Timothy Springer and Motomu Shimaoka (Immune Disease Institute), and his laboratory research focuses on elucidation of sepsis pathophysiology and understanding the impact of anesthetics on perioperative immune function. In addition, he is interested in performing risk stratification of noncardiac surgery in patients with congenital heart disease.